UCL Cancer Institute works in partnerships with specialist Centres that cut across both Institute departments and wider UCL departments and divisions to further collaboration and interdisciplinary research.
The Centre focuses on genomics studies, from cancer classification to personal genomics and patient stratification.
The UCL Cancer Domain underpins UCL’s distinctive cross-disciplinary approach to cancer research, bringing researchers together to advance our understanding of cancer and develop improved diagnostics and treatments.
The UCL Cancer Institute Cancer Immunotherapy Accelerator (CITA) has been developed to maximise the potential of immunotherapeutics to cure more cancer sooner and integrates key expertise across UCL and UCL Hospitals, King’s College London, The Francis Crick Institute, The Royal Marsden Hospital and Barts Cancer Institute.
The Cancer Research UK-UCL Centre is part of a national network of centres funded by Cancer Research UK dedicated to delivering world-leading research, improved patient care and greater local engagement.
The CRUK Centre Brain Tumour Centre of Excellence aims to help deliver a step change in glioma research in the UK by bringing together world-leading experts to advance understanding of the biology underpinning the disease and explore new avenues for diagnosis and personalised treatment.
The CRUK Lung Cancer Centre of Excellence at Manchester and UCL brings together the unique and complementary strengths of our partner organisations to create a collaborative environment in which integrated lung cancer research can flourish.
A partnership between UCL, Barts/QMUL, King Health Partners and the Francis Crick Institute to form the CRUK City of London (CoL) Centre focused on research in Cancer Biotherapeutics.
The Comprehensive Cancer Imaging Centre (CCIC) is a major collaboration between UCL and King's College London, supported by funding from Cancer Research UK, Engineering & Physical Sciences Research Council, Medical Research Council and Department of Health (England).
The Experimental Cancer Medicine Centre (ECMC) Network is a unique UK-wide initiative jointly funded by Cancer Research UK and UK Health Departments. UCL ECMC is committed to performing world-class clinical cancer research to develop new cancer therapies.
A new transatlantic research alliance between CRUK, UCL, Canary Center at Stanford University, the University of Cambridge, the OHSU Knight Cancer Institute and the University of Manchester focused on developing radical new strategies and technologies to detect cancer at its earliest stage.
The NIHR BTRU in Stem Cells and Immunotherapies is an inter-disciplinary partnership between University College London (UCL), King's College London, Queen Mary University of London and NHS Blood and Transplant (NHSBT). It supports the NHSBT with research to improve the supply of blood products and stem cells for transplantation and the delivery of new therapies.